Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy

FRIDAY, Aug. 14, 2026 (HealthDay News) -- Many people with atypical Alzheimer disease (AD) do not meet eligibility criteria for anti-amyloid therapies (AAT), according to a study published online Aug. 5 in Neurology.Dror Shir, M.D., from the Mayo Clinic in Jacksonville, Florida, and colleagues conducted a retrospective eligibility analysis of patients with atypical AD. Theoretical eligibility for AAT was assessed by applying inclusion and exclusion criteria from landmark clinical trials and appropriate use criteria for lecanemab and donanemab.The cohort included 184 patients with biomarker-confirmed atypical AD: 53.3 percent with posterior cortical atrophy (PCA), 22.8 percent with logopenic variant primary progressive aphasia (lvPPA), 20.1 percent with dysexecutive AD (dAD), and 3.8 percent with corticobasal syndrome because of AD (CBS-AD). The researchers found a difference in functional impairment by phenotype, with lvPPA more often diagnosed at the mild cognitive impairment/very mild stage and PCA and dAD more often presenting with mild dementia; no difference was seen in the time from symptom onset to diagnosis. Differences were seen in the Mini-Mental State Examination scores, with lower scores in PCA and lvPPA than in CBS-AD (median, 21, 21, and 27, respectively). Overall, 70 to 85 percent of patients would not meet treatment criteria, depending on the eligibility framework applied. The primary drivers of ineligibility were bedside cognitive thresholds (50 to 67 percent of exclusions), despite most patients having early symptomatic disease. In addition, imaging-based exclusions and severity thresholds were common (22 to 27 percent and 19 to 23 percent, respectively). Across phenotypes, reasons for ineligibility were similar."Our findings suggest that treatment criteria may unintentionally exclude many of these patients, even when they are in the early stages of disease," Shir said in a statement.Several authors disclosed ties to the biopharmaceutical industry.Abstract/Full TextEditorial (subscription or payment may be required).Sign up for our weekly HealthDay newsletter

Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy

Related Stories

Imaging Turnaround Time Increased From 2023 to 2024

2005 to 2023 Saw Decrease in DXA Testing for Osteoporosis Screening

Dexamethasone Eye Drops Can Reduce Progression to ROP Requiring Treatment

Women With Parkinson's More Likely To Have Brain Changes Related To Alzheimer's